{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-001492","form_type":"8-K","ticker":"GUTS","cik":"0001572616","company_name":"FRACTYL HEALTH, INC.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.493058+00:00","generated_at":"2026-05-16T11:39:47.226121+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fractyl Health outlines 2026 milestones for Revita and Rejuva; cash $85.6M","bullets":["Preliminary unaudited cash $81.5M at Dec 31, 2025; plus $4.1M from Tranche A warrant exercises on Jan 2, 2026 gives $85.6M.","Revita: 6-month randomized REMAIN-1 Midpoint data due late Jan 2026; potential PMA filing in H2 2026.","Rejuva: RJVA-001 first-in-human dosing expected in H2 2026 subject to CTA authorization; regulatory feedback in Q2 2026.","Cash runway projected through early 2027 to fund all planned 2026 clinical and regulatory milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-001492","json":"https://secwatch.observer/filing/0001193125-26-001492.json","markdown":"https://secwatch.observer/filing/0001193125-26-001492.md","text":"https://secwatch.observer/filing/0001193125-26-001492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1572616/000119312526001492/0001193125-26-001492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1572616/000119312526001492/guts-20260105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:39:47.226121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}